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Oncogene-dependent function of BRG1 in
hepatocarcinogenesis
Pan Wang1, Xinhua Song1, Dan Cao2, Kairong Cui3, Jingxiao Wang1, Kirsten Utpatel4, Runze Shang1,5,
Haichuan Wang 1,6, Li Che 1, Matthias Evert4, Keji Zhao3, Diego F. Calvisi4,7 and Xin Chen 1
Abstract
Hepatocellular carcinoma (HCC) is the major type of primary liver cancer. Genomic studies have revealed that HCC is a
heterogeneous disease with multiple subtypes. BRG1, encoded by the SMARCA4 gene, is a key component of SWI/SNF
chromatin-remodeling complexes. Based on TCGA studies, somatic mutations of SMARCA4 occur in ~3% of human
HCC samples. Additional studies suggest that BRG1 is overexpressed in human HCC specimens and may promote HCC
growth and invasion. However, the precise functional roles of BRG1 in HCC remain poorly delineated. Here, we
analyzed BRG1 in human HCC samples as well as in mouse models. We found that BRG1 is overexpressed in most of
human HCC samples, especially in those associated with poorer prognosis. BRG1 expression levels positively correlate
with cell cycle and negatively with metabolic pathways in the Cancer Genome Atlas (TCGA) human HCC data set. In a
murine HCC model induced by c-MYC overexpression, ablation of the Brg1 gene completely repressed HCC formation.
In striking contrast, however, we discovered that concomitant deletion of Brg1 and overexpression of c-Met or mutant
NRas (NRASV12) triggered HCC formation in mice. Altogether, the present data indicate that BRG1 possesses both
oncogenic and tumor-suppressing roles depending on the oncogenic stimuli during hepatocarcinogenesis.
Introduction
Primary liver cancer is the sixth most common tumor in
the world1. Hepatocellular carcinoma (HCC) is the pre-
dominant subtype of liver cancer. Owing to the lack of
specific symptoms, most HCCs are diagnosed at advanced
stage. Therapeutic approaches for advanced HCC are
limited. Indeed, these HCC patients are eligible to treat-
ment with Sorafenib and Regorafenib multi-kinase inhi-
bitors, but only limited benefits are observed2. Recently,
immune checkpoint inhibitors have also been approved as
second line treatment with marked responses, but only in
~20% of patients3. Thus, it is imperative to elucidate the
molecular mechanisms underlying hepatocarcinogenesis
in order to develop innovative and more effective thera-
pies against HCC.
ATP-dependent chromatin remodeling is involved in
controlling chromatin structure that in turn regulates
many physiological and pathological processes4. Switch-
ing/sucrose non-fermentable (SWI/SNF) complexes are
members of the family of ATP-dependent chromatin-
remodeling complexes, which consists of ~15 subunits5.
Mammalian SWI/SNF complexes family further divided
into two major complexes, including the BRG1-associated
factor (BAF) complex and the poly-bromo BRG1-asso-
ciated factor (PBAF) complexes6. All complexes contain
one of two mutually exclusive catalytic ATPase subunits,
either BRG1 (encoded by SMARCA4) or BRM (encoded
by SMARCA2)7. The function of SWI/SNF is to regulate
gene transcription by rearranging nucleosome positions
and histone–DNA interactions, thus facilitating the
transcriptional activation or repression of target genes4.
The complexes control a wide variety of physiological and
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cellular processes, including tissue specificity, inflamma-
tory processes, immunological responses, and early
embryonic development8. Recent exome sequencing stu-
dies have revealed that SWI/SNF subunits of chromatin-
remodeling complexes are mutated in over 20% of human
tumors7. The key role of SWI/SNF in HCC has been
highlighted by the fact that the SWI/SNF complex sub-
units, ARID1A and ARID2, are mutated in 7% and 5% of
human HCC samples, respectively9, thus representing
some of the most mutated genes in HCC.
BRG1, the core subunit of the SWI/SNF complex, is
essential for DNA repair, differentiation, and organ
development10. However, the role of mutated BRG1 in
tumorigenesis remains largely controversial. Although
some human tumors show overexpression of BRG1, other
display instead a suppression of BRG1 expression11–14. In
addition, BRG1 can interact with both proliferation pro-
moting and inhibiting genes15,16. Altogether, these data
envisage the possibility that BRG1 may function either as
an oncogene or tumor suppressor gene in a context-
dependent manner. The contradictory function of BRG1
has been also observed in human HCC. For instance, it
has been shown that the SNU398 HCC cell line harbors a
homozygous deletion of the SMARCA4 gene. In addition,
copy number loss at SMARCA4 locus was detected in 14%
of primary HCC tumors11. In striking contrast, a positive
correlation between increased BRG1 expression and HCC
aggressiveness was described17. Furthermore, Benedikt
et al.18 showed that BRG1 promotes hepatocarcinogenesis
by regulating proliferation and invasiveness.
In this manuscript, we systematically analyzed BRG1
expression as well as SMARCA4 mutation status in
human HCC samples. Using conditional Brg1 KO mice
and oncogene-driven HCC murine models, we investi-
gated the functional role(s) of Brg1 in hepatocarcino-
genesis. Our data support the hypothesis that BRG1
functions predominantly as an oncogene in HCC. How-
ever, BRG1 possesses also a tumor suppressive role in a
small percentage of human HCCs.
Results
BRG1 expression and SMARCA4 mutation status in human
HCC samples
To study BRG1 in human HCCs, we first analyzed
BRG1 expression levels using TCGA human HCC data
set. We discovered that BRG1 expression levels are
upregulated in most human HCC samples when com-
pared with non-tumor liver tissues (Fig. 1a), although
~ 3% of HCCs have lower BRG1 expression. This result
was independently validated via the Fudan HCC data set
(Fig. 1b). Consistent with a previous report19, high
expression of BRG1 is associated with poor HCC patient
survival (Fig. 1c).
To further validate these results, we evaluated BRG1
mRNA levels in our collection of human normal livers,
HCCs, and corresponding non-tumorous surrounding
livers (n= 60; Supplementary Fig. 1A). We found that
mRNA expression of BRG1 was significantly higher in
HCC when compared with non-tumorous surrounding
livers and normal livers (Supplementary Fig. 1A).
Fig. 1 BRG1 expression, mutation, and survival analysis in human data sets. a Scatter-bar plot of BRG1 mRNA expression in TCGA LIHC data set.
b Scatter-bar plot of BRG1 mRNA expression in Fudan data set. c Kaplan–Meier survival plot from UALCAN using TCGA LIHC data set. d Heatmap of
BRG1 mRNA expression in TCGA LIHC data set with multiple mutation status of well-known oncogenes in HCC. ST surrounding tissue, HCC
hepatocellular carcinoma; ****p < 0.0001.
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Furthermore, the most pronounced upregulation of BRG1
was detected in human HCC with poorer prognosis
(HCCP; Supplementary Fig. 1B). No significant associa-
tion between the mRNA levels of BRG1 and clin-
icopathologic features of the patients, such as gender,
etiology, presence of cirrhosis, alpha-fetoprotein levels,
and tumor size was found (data not shown). We also
performed immunostaining of BRG1 in paired human
HCC and surrounding non-tumor liver tissues. Again, we
found that BRG1 is expressed at higher levels in most
human HCC samples (Supplementary Fig. 2A, B). How-
ever, a small percentage of human HCCs show very low
BRG1 protein expression (Supplementary Fig. 2C, E). In
most of the non-tumor liver tissues, there is minimum
expression of BRG1 in hepatocytes, whereas strong BRG1
expression could be detected in bile duct cells, lympho-
cytes, and macrophages (Supplementary Fig. 2D).
Next, we explored SMARCA4mutation status in human
HCC samples. Among the 360 HCCs in the TCGA
database, 10 HCCs harbored a SMARCA4 mutation
(Supplementary Fig. 3A). As SMARCA4 mutations are
rather rare, we expand the search into COSMIC data-
base20 (Supplementary Fig. 3B). In total, SMARCA4
mutation rate was found to be ~2.4% in human HCCs. It
is worth to note that SMARCA4 mutations are generally
point mutations in HCCs, and these mutations scatter
throughout the BRG1 protein sequence, with no clear hot
spots (Supplementary Fig. 3B).
We then analyzed SMARCA4 mutation and BRG1
expression levels in relationship to other common
mutations, including mutations in TP53, CTNNB1,
AXIN1, TSC1/2, and ARID1A/2 in human HCC samples
(Fig. 1d). We did not observe any statistically significant
correlation between SMARCA4 mutations or BRG1
expression levels with these common genetic events in
human HCCs.
Finally, we analyzed the genes whose expression levels
correlate with BRG1 mRNA expression in human HCCs
using the TCGA data set9. We identified 1915 genes
whose expression levels positively correlate with BRG1
mRNA level, and 1067 genes negatively correlate with
BRG1 mRNA level (Supplementary Tables 1, 2). Among
the positively co-expressed genes, BRG1 expression had a
strong correlation with CDK4, CCNB1, and CCNE1
(Supplementary Fig. 4). KEGG pathway analysis revealed
that BRG1 positively co-expressed genes were sig-
nificantly enriched in cell cycle pathway and DNA repli-
cation and HCC (Fig. 2a), which further implicates the
role of BRG1 in promoting HCC proliferation. Interest-
ingly, BRG1 negatively co-expressed genes were highly
enriched in metabolic pathways, including vital hepato-
cyte functions, such as primary bile acid biosynthesis,
drug metabolism, steroid hormone biosynthesis, etc. The
result indicates that high BRG1 expression correlates with
poorly differentiated status in human HCC (Fig. 2b).
Similar results were obtained in GO analysis (Supple-
mentary Fig. 5).
In summary, our findings indicate that BRG1 expression
is upregulated in most human HCC samples, and high
expression of BRG1 correlates with poor prognosis. At the
molecular level, BRG1-elevated levels are positively asso-
ciated with increased HCC cell proliferation and
decreased differentiation status. However, mutations in
SMARCA4 or BRG1 low expression can be found in a
Fig. 2 KEGG pathway analysis of BRG1 co-expressed genes. a Positively co-expressed genes. b Negatively co-expressed genes. Enrichment
number means the percentage of BRG1 co-expressed genes in the pathway.
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small percentage of human HCCs. Thus, based on
expression levels, BRG1 may predominantly function as
an oncogene along hepatocarcinogenesis, but can also act
as a tumor suppressor in a small percentage of
human HCC.
Loss of Brg1 does not affect liver homeostasis
To investigate the functional role(s) of Brg1 in hepato-
carcinogenesis, we applied genetic approaches using the
Brg1f/f mice. First, we investigated whether ablation of
Brg1 affects liver homeostasis. For this purpose, we
injected Brg1f/f mice with adeno-associated virus encoding
null (AAV-null) or Cre (AAV-Cre) plasmid under liver
specific thyroxine-binding globulin (TBG) promoter (Fig.
3a). We found that AAV-Cre infection effectively deleted
Brg1 in mouse hepatocytes (Fig. 3b, c) in both male and
female mice. The residual Brg1 expression detected in
AAV-Cre mice by western blotting reflected Brg1
expression in non-parenchymal cells in the liver, which
could be clearly visualized by immunostaining (Fig. 3c).
Consistent with a previous report21, we found that loss of
Brg1 did not affect liver homeostasis: indeed, liver/body
weight ratio (Fig. 3d), liver histology as well as hepatocyte
proliferation (Fig. 3c) were equivalent in AAV-null and
AAV-Cre mice.
To identify the genes regulated by Brg1, we compared
gene expression patterns of liver tissues from AAV-Null
and AAV-Cre mice using RNASeq. We discovered that 68
genes were upregulated, and 79 genes downregulated in
Brg1(−) liver tissues when compared with Brg1(+) liver
tissues (Supplementary Figs. 6, 7; and Supplementary
Table 3). Several selected genes were further validated
using qRT-PCR, supporting the reliability of RNASeq
results (Supplementary Fig. 8). Despite the fact that Brg1
is a core component of the SWI/SNF complex, loss of
Brg1 had a relatively limited impact on global gene
expression patterns. These findings suggest that addi-
tional molecules in the complex may compensate for the
loss of Brg1 to preserve liver homeostasis.
Loss of Brg1 inhibited c-MYC driven hepatic carcinogenesis
Amplification of c-MYC is one of the most frequent
genetic events along HCC development and progres-
sion22. In mice, hydrodynamic transfection of c-MYC
Fig. 3 Ablation of Brg1 in mouse hepatocytes does not affect liver homeostasis in adult mice. a Study design. b Protein expression of Brg1 in
the liver of Brg1flf AAV-Cre and of Brg1flf AAV-null mice analyzed by western blot analysis. c Gross image, H&E staining, Ki67, and Brg1 staining of Brg1flf
AAV-Cre and of Brg1flf AAV-null mice. d Liver body weight ratio of Brg1flf AAV-Cre (n= 6) and Brg1flf AAV-null mice (n= 7).
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rapidly induces the formation of poorly differentiated
HCC, and mice have to be euthanized owing to high liver
tumor burden by ~6 weeks post hydrodynamic injec-
tion23, supporting the oncogenic role of c-MYC in
the liver.
We found that nuclear Brg1 staining could be readily
detected in c-MYC mouse HCC tissues (Supplementary
Fig. 9). We have previously performed global gene
expression analysis of c-MYC mouse HCC and normal
mouse liver tissues using microarrays23. We investigated
whether BRG1-correlated genes are differentially expres-
sed in c-MYC mouse HCCs. Specifically, 1495 BRG1
positively correlated genes and 799 BRG1 negatively
correlated genes were identified in the mouse data set.
Heatmap analysis revealed that most of the BRG1 posi-
tively correlated genes were upregulated in c-MYC HCC
samples, whereas most of the BRG1 negatively correlated
genes were downregulated in c-MYC HCC (Supplemen-
tary Fig. 10A, B). Indeed, we found that 11.6% of total
genes were upregulated in c-MYC HCC, 26.3% of the
BRG1 positively correlated genes were upregulated, and
3.6% of BRG1 negatively correlated genes were upregu-
lated. Similarly, 9.5% of total genes were downregulated in
c-MYC HCC. 2.9% of the BRG1 positively correlated
genes were downregulated, and 47.9% of BRG1 negatively
correlated genes were downregulated (Supplementary Fig.
10C). Altogether, our study demonstrates the Brg1 is
upregulated in c-MYC mouse HCC, leading to the acti-
vation of Brg1-correlated gene expression signature.
To investigate the functional contribution of Brg1 in c-
MYC driven HCC, we hydrodynamically injected c-MYC
with CRE plasmids into Brg1f/f mice (c-MYC/CRE) (Fig.
4a). This approach allowed the overexpression of c-MYC
oncogene while simultaneously deleting Brg1 in the same
set of mouse hepatocytes. As control, additional Brg1f/f
mice were injected with c-MYC and pCMV empty vector
plasmid (c-MYC/pCMV) (Fig. 4a). All c-MYC/pCMV
injected Brg1f/f mice developed high liver tumor burden
and became moribund between 7.6 and 12 weeks post
injection. In striking contrast, all c-MYC/CRE injected
Brg1f/f mice appeared to be healthy with no signs of tumor
development (Fig. 4b). Consistently, c-MYC/pCMV mice
had high liver/body weight ratio, whereas c-MYC/CRE
mice demonstrated similar ratio to that seen in normal
mice (Fig. 4c). Grossly, numerous tumor nodules could be
found in c-MYC/pCMV liver, but not in c-MYC/CRE
livers (Fig. 4d). Histological evaluation revealed the poorly
differentiated and highly proliferative (as shown by
immunostaining of Ki67) HCC in c-MYC/pCMV mice.
All tumor cells were Brg1(+). In contrast, histologically
normal liver was detected in c-MYC/CRE mice with few
Ki67(+) cells. It is important to clarify that we applied
hydrodynamic injection in combination with sleeping
beauty-mediated somatic integration to stably express
genes into the mouse hepatocytes. This approach could
stably transfect ~1–5% of mouse hepatocytes24. When we
transfected c-MYC/CRE into Brg1f/f mice, we over-
expressed c-MYC while deleting Brg1 in a small percen-
tage of hepatocytes. Indeed, using immunostaining,
sporadic Brg1(−) hepatocytes could be readily detected in
c-MYC/CRE injected Brg1f/f mouse liver tissues (Fig. 4d),
supporting the successfulness of the expression of the
injected plasmids. Nonetheless, these transfected hepa-
tocytes were unable to progress into tumor cells.
Altogether, these findings demonstrate that Brg1 is
indispensable for c-MYC induced HCC formation in vivo.
Loss of Brg1 cooperates with c-MET or RASV12 to promote
HCC development in mice
Loss of BRG1 expression and SMARCA4 loss-of-
function mutations were identified in a small subset of
human HCC samples, suggesting that BRG1 may also
function as a tumor suppressor. To test this hypothesis,
we overexpressed CRE in Brg1f/f mice, with consequent
deletion of Brg1 in a small subset of mouse hepatocytes.
We found that sporadic deletion of Brg1 alone is unable to
promote liver tumor formation (Supplementary Fig. 11).
This observation is consistent with our studies expressing
AAV-CRE into Brg1f/f mice, resulting in the deletion of
Brg1 in all hepatocytes (Fig. 3). Overall, these results
suggest that loss of Brg1 per se is not oncogenic.
Previous data indicate the ubiquitous activation of the
RAS/MAPK signaling in HCC25, supporting a pivotal role of
this signaling cascade along hepatocarcinogenesis. In the
mouse liver, overexpression of either c-MET or an activated
mutant form of NRAS (NRASV12) is able to activate the
RAS/MAPK signaling, although none of these genes alone is
capable of inducing HCC formation in vivo26. Thus, we
hypothesized that loss of Brg1may cooperate with c-MET or
NRASV12 to induce liver tumor development in mice. To
validate our hypothesis, we hydrodynamically injected Brg1f/f
mice with CRE plasmid and c-MET (Brg1−/−/c-MET) or
NRASV12 (Brg1−/−/ NRASV12) (Fig. 5a). Strikingly, liver
tumors developed in Brg1−/−/c-MET and Brg1−/−/
NRASV12 mice by 20–30 weeks post injection (Fig. 5b, c).
Grossly, numerous tumor nodules were detected on the liver
surface (Fig. 5d). Histologically, hepatic adenomas and well-
differentiated HCC were observed in Brg1−/−/c-MET and
Brg1−/−/NRASV12 mice (Fig. 5d). Tumor cells were pro-
liferative, as demonstrated by Ki67 immunostaining (Fig.
5d). Importantly, immunolabeling with the Brg1 antibody
revealed that HCC cells were derived from Brg1(−) hepa-
tocytes and did not express Brg1 (Fig. 5d).
As overexpression of c-MET occurs frequently in
human HCCs, whereas NRAS mutations are rather rare,
we focused on the Brg1−/−/c-MET mouse HCC model for
additional studies. At the biochemical level, ectopically
injected c-MET and activation of p-Akt and p-Erk
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downstream of c-MET were detected in Brg1−/−/c-MET
mouse HCC tissues (Supplementary Fig. 12). It is worth to
note that tumor development was rather slow in these
mice (Supplementary Fig. 13A). For instance, c-MET and
activated mutant form of β-Catenin (β-CateninS45Y) are
able to induce HCC formation within 8 weeks post
injection27. Similarly, loss of Pten (sgPten) synergizes with
c-MET to promote hepatocarcinogenesis within
~11–17 weeks post injection28. Furthermore, although c-
MET/β-CateninS45Y mouse HCC tissues expressed high
levels of alpha-fetoprotein (Afp), Brg1−/−/c-MET HCCs
expressed Afp at very low levels, similar to those in nor-
mal liver (Supplementary Fig. 13B). We investigated the
correlated between AFP and BRG1 in human HCC sam-
ples using the TCGA data set. We found that there is a
statistically significant positive correlation between BRG1
expression and AFP expression in human HCCs (Sup-
plementary Fig. 13C). Thus, Brg1−/−/c-MET mice could
represent an excellent Afp(−) murine HCC model.
Altogether, our investigation demonstrates that Brg1
can function as a tumor suppressor, and loss of Brg1 is
able to cooperate with c-MET or NRASV12 to induce liver
tumor development in mice.
Discussion
SWI/SNF complex is an important chromosome
remodeling factor and regulates the expression of genes in
the cells. BRG1 and BRM are two Helicases/ATPases in
the SWI/SNF complex. Although BRG1 is part of the BAF
complex, BRM is found in both BAF and PBAF com-
plexes. Importantly, the presence of BRM and BRG1 is
mutually exclusive in the BAF complex29. Mounting evi-
dence indicates that the deregulation of SWI/SNF com-
plex contributes to cancer development, including HCC.
For instance, ARID1A and ARID2 are among the most
frequently mutated genes in HCC30. However, the func-
tional roles of BRG1 in liver carcinogenesis remain con-
troversial. It was found that a SNP in SMARCA4 gene,
namely rs11879293, is associated with decreased risk of
developing HCC31. In human HCCs, loss-of-function
mutations of SMARCA4 are present in a small percentage
of samples30, and the homozygous deletion of SMARCA4
was detected in the SNU398 HCC cell line32. These
results support a tumor suppressor role for BRG1 in HCC.
However, multiple studies have demonstrated that BRG1
expression is upregulated in human HCCs. Over-
expression of BRG1 in HCC cells promotes cell
Fig. 4 Brg1 inactivation prevents hepatocellular carcinoma (HCC) formation in c-MYC mice. a Study design. b Survival analysis of Brg1f/f mice
bearing c-MYC/pCMV and c-MYC /CRE tumors using the Kaplan–Meier survival method. c Liver body weight ratio of Brg1f/f c-MYC/pCMV (n= 9) and
c-MYC /CRE mice (n= 11). d Gross image, H&E staining, Brg1, and Ki67 staining of Brg1f/f c-MYC/pCMV and c-MYC /CRE mice.
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proliferation and invasion19. These results suggest that
BRG1 may paradoxically function as an oncogene in HCC
as well.
In this manuscript, we systematically analyzed BRG1
expression patterns and SMARCA4 mutation status in
human HCC samples. In addition, we investigated the
functional roles of Brg1 in hepatocarcinogenesis using
mouse modeling. Consistent with previous reports, we
found that BRG1 expression is upregulated in most of
human HCC samples (Fig. 1 and Supplementary Fig. 2).
Importantly, we established a BRG1-correlated gene
expression signature. Pathway analysis demonstrated that
the high expression of BRG1 correlates with cell cycle and
DNA replication, whereas low expression of BRG1 cor-
relates with liver metabolism. These data clearly support
the finding that high BRG1 expression is associated with
increased cell proliferation and decreased hepatocyte
differentiation in human HCCs. This observation is fur-
ther supported by the fact that high BRG1 levels correlate
with poor patient survival.
To further validate the oncogenic roles of BRG1, we
applied mouse genetic approaches. We found that c-
MYC-induced mouse HCC exhibit high levels of BRG1
expression. We analyzed BRG1-correlated genes in c-
MYC mouse HCC samples. We found that genes
correlated with high BRG1 are also enriched in c-MYC
HCC upregulated gene list, whereas genes correlated with
low BRG1 are enriched in c-MYC HCC downregulated
gene list (Supplementary Fig. 10). These bioinformatics
analyses provide unbiased support of the activation of
BRG1 in c-MYC induced liver cancer development. Next,
we expressed c-MYC while simultaneously deleting Brg1
in mouse hepatocytes. We discovered that ablation of
Brg1 completely prevented c-MYC driven HCC formation
in vivo. The study, for the first time, provides in vivo
evidence supporting the oncogenic role of BRG1 along
hepatocarcinogenesis. It is worth to note that using c-
MYC transgenic mice, Sun et al.33 showed that loss of
Arid1a, another member of the SWI/SNF family, ham-
pered c-MYC-driven HCC initiation in mice. Altogether,
our data indicate the key role of the SWI/SNF chromo-
somal remodeling factors in c-MYC-induced hepato-
carcinogenesis. It is well-known that c-MYC is a major
oncogene in HCC, whose direct targeting has proven to
be difficult. Thus, our study suggests that targeting BRG1
or other members of the SWI/SNF complexes may be an
alternative approach to target HCC with c-MYC ampli-
fication and/or overexpression.
Although BRG1 expression is found to be upregulated
in the vast majority of human HCC samples, it is worth to
Fig. 5 Brg1 deletion cooperates with c-MET and NRASV12 to induce liver tumor formation in mice. a Study design. b Survival analysis of Brg1f/f
mice injected CRE plasmid and c-MET (Brg1−/−/c-MET) or NRASV12 (Brg1−/−/ NRASV12). c Liver body weight ratio of Brg1−/−/c-MET (n= 21) and
Brg1−/−/ NRASV12mice (n= 9). d Gross image, H&E staining, Brg1, and Ki67 staining of Brg1−/−/c-MET and Brg1−/−/ NRASV12mice.
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note that a small percentage of HCCs have low expression
of BRG1 or harbor inactivating SMARCA4 mutations,
suggesting a possible tumor suppressor role of BRG1.
Importantly, in a previous study, BRG1 has been shown to
possess both oncogenic and tumor suppressor roles in
pancreatic cancer34. In addition, the study by Sun et al.33
demonstrated that ARID1A has context-dependent roles
as tumor suppressor and oncogene in liver cancer.
Therefore, we investigated the possible tumor-
suppressing functions of Brg1 in mice and found that
deletion of Brg1 cooperates with activated Ras/MAPK
signaling (via either c-MET or NRASV12 overexpression)
to promote HCC development in mice. Comparing with
other common oncogenic signals, such as loss of Pten or
activation of the Wnt/β-Catenin, HCC induced by loss of
Brg1 were characterized by longer tumor latency. Pre-
viously, we have established multiple HCC models by the
combination of oncogenes, such as Akt/NRas(V12)35,
sgPten/c-Met28, c-Met/β-Catenin36, and c-Met/sgAxin137.
All these HCC models have high levels of Afp. Interest-
ingly, Brg1−/−/c-MET mouse HCCs are Afp(−). Con-
sistently, we have found that low expression of BRG1 is
associated with low AFP levels in human HCC samples.
To the best of our knowledge, Brg1−/−/c-MET HCC is the
first murine HCC model with low Afp. This model could
be very useful in studying therapeutic approaches against
Afp(+) and Afp(−) HCC.
One of the key conclusion from our study is that BRG1
has context-dependent tumor-suppressing or oncogenic
roles during hepatocarcinogenesis. It is worth to note that
there is increasing evidence, highlighting the importance
of context-dependent control of gene expression in can-
cer. The molecular mechanisms underlying the dual role
of BRG1 remain unclear. Shi et al.38 discovered that BRG1
functions as an oncogene in leukemia via regulating c-
MYC and its transcriptional program. In human HCC
samples, SMARCA4 and MYC are found to be in a gene-
regulatory network39. The results are consistent with our
current study indicating that Brg1 is required for c-MYC-
driven HCC formation. The biochemical cross-talk
between BRG1 and c-MET has not been reported pre-
viously. Our investigation, therefore, provides novel
insights into how these two pathways may act in concert
to induce HCC development. Obviously, further experi-
ments are required to elucidate the mechanisms by which
BRG1 functions to regulate hepatocarcinogenesis.
At present, precision medicine has become a norm in
oncology. It is important to recognize that there is no
one-size-fits-all therapy. Although some mutations or
genetic alternations are relatively rare, they may represent
excellent opportunities for targeted therapy. Low BRG1
expression or loss of function mutations of SMARCA4
may only account for a total of ~5% of HCC. However,
these HCCs may be sensitive to specific treatment
strategies. For instances, previous studies have shown that
EZH2 inhibition sensitizes SMARCA4 mutant lung can-
cers to Topoisomerase 2 inhibitors40. BRG1-deficient
cancer was found to be highly sensitive to BRM/
SMARCA2 inhibition41. It would be very useful to test
these treatment options in BRG1 low or SMARCA4
mutant HCCs, and Brg1−/−/c-MET mouse HCC repre-
sents an excellent murine HCC model to challenge these
treatment strategies.
In summary, BRG1 possesses oncogenic and tumor
suppressive roles that are context and gene dependent. A
better understanding of the consequences of either
overexpression or loss of BRG1 in HCC would be
necessary for the establishment of effective treatments
against this deadly disease.
Materials and methods
Human data retrieval and analysis
The data illustrated here were generated by the Cancer
Genome Atlas (TCGA) Research Network: https://www.
cancer.gov/tcga and the Catalogue of Somatic Mutations
in Cancer (COSMIC): https://cancer.sanger.ac.uk/cosmic.
We used TCGA expression data that were frozen in 2/25/
2015. The overall sample size is 410, including 50 sur-
rounding liver tissues (ST) and 360 primary hepato-
carcinoma (HCC) from TCGA LIHC database. The
mutation and copy number alteration data were extracted
with cBioportal (http://www.cbioportal.org)42,43. Survival
plot was obtained from UALCAN44. Data were analyzed
and visualized in R using multiple packages. Heatmap was
drawn with Complexheatmap45. The BRG1 expression
data were normalized with Mean plus 1.5-fold SD of the
ST group and ordered ascendingly. Mutations on TP53,
CTNNB1, AXIN1, TSC1, TSC2, ARID1A, ARID2, and
BRG1 were also included in the heatmap. Scatter-bar plot
of the mRNA expression of TCGA and Fudan data sets
were drawn with Graphpad Prism 7.0 (GraphPad Soft-
ware, San Diego, US). Scatter plot of correlation was made
using ggplot2 (H. Wickham. ggplot2: Elegant Graphics for
Data Analysis. Springer-Verlag New York, 2016.) and
DEGreport (Pantano L 2014; DEGreport: Report of DEG
analysis. R package version 1.0.0.). Pearson correlation
was used to test correlation between the log2 mRNA
expression of different genes with BRG1. Positively co-
expressed genes and negatively co-expressed genes were
extracted from cBioportal with a threshold of |r| > 0.3 and
p value < 0.05 (Supplementary Table 4). Subsequently, we
conducted KEGG and GO pathway analysis using
limma46, GO.db (Carlson M 2019; GO.db: A set of anno-
tation maps describing the entire Gene Ontology. R pack-
age version 3.8.2.) and KEGGREST (Tenenbaum D 2019;
KEGGREST: Client-side REST access to KEGG. R package
version 1.24.0.). Top 20 KEGG pathways enriched in
BRG1 positively correlated or negatively correlated genes
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were visualized by scatter plot. Top 30 GO (Biological
Process) pathways were visualized by bar plot.
Human tissue samples
A collection of 60 frozen HCC and corresponding non-
tumorous surrounding livers was used. Tumors were
divided in HCC with shorter/poorer (HCCP; n= 29) and
longer/better (HCCB; n= 31) survival, characterized by <
3 and ≥ 3 years’ survival following partial liver resection,
respectively. The clinicopathological features of liver
cancer patients are summarized in Supplementary Table 5
HCC specimens were collected at the Medical Uni-
versities of Regensburg (Regensburg, Germany) and Sas-
sari (Sassari, Italy). Institutional Review Board approval
was obtained at the local Ethical Committee of the
Medical Universities of Regensburg and Sassari. Informed
consent was obtained from all individuals.
RNASeq analysis of mouse liver tissues
RNA was extracted from AAV-Cre and AAV-Null
infected mouse liver tissues. RNAseq libraries were gen-
erated as previously described47. In brief, total RNAs were
reverse transcribed by SuperScript II (Invitrogen,
Cat#18064-014) with oligo-dT and LNA-containing TSO
primers. cDNAs were pre-amplified by using KAPA HIFI
HotStart ReadyMix (Kapabiosystems Cat#KK2602) with
IS PCR. PCR amplified cDNAs were purified by Ampure
XP beads (Beckman Coulter, Cat#A63881) and sonicated
to 200–400 bps by Bioruptor Pico (Diagenode). Sonicated
cDNAs were used for RNAseq library preparation and
sequencing as described previously47.
Plasmids and reagents
The plasmids used for the study, including pT3EF1α-c-
MYC, pT3EF1α-c-MET, pT2-Caggs-NRASV12, pCMV,
pCMV-Cre, and pCMV/sleeping beauty transposase (SB)
have been described in our previous publications48,49. All
plasmids were purified by using the Endotoxin free Maxi
prep kit (Sigma-Aldrich, St. Louis, MO) before injection.
The AAV8.TBG.PI.Cre.rBG and AAV8.TBG.PI.Null.Bgh
vectors were obtained from the University of Pennsylvania
Gene Therapy Core Services.
Animals and treatments
Brg1flf mice (C57BL/6 background) were kindly pro-
vided to us by Dr. Matthias Hebrok of UCSF50. Mice were
crossed for six generations with FVB/N mice to generate
Brg1flf mice in FVB/N background. To deplete Brg1 gene
specifically in adult mouse hepatocytes, six-week old
Brg1flf mice were infected with 4 × 1011 genome copies
adeno-associated viral with TBG promoter-Cre recombi-
nase (AAV8.TBG.PI.Cre.rBG) by tail vein injection and
waited 3 weeks for gene deletion. An AAV8.TBG.PI.Null.
Bgh was injected into additional Brg1flf mice and used as
control. Sleeping beauty-mediated hydrodynamic injec-
tion was performed as described24. The detailed plasmid
mixture information is reported in Supplementary Table
6. Mice were housed, fed, and monitored in accord with
protocols approved by the Committee for Animal
Research at the University of California San Francisco
(San Francisco, CA). Mice were closely monitored for
liver tumor development as palpable abdominal masses.
Mice were killed at indicated time points or when they
became moribund or develop large abdominal masses.
Liver weight, body weight, as well as surface tumor nodule
numbers were recorded.
Immunohistochemistry (IHC)
Liver specimens were fixed in 4% paraformaldehyde
overnight at 4 °C then embedded in paraffin. Tissue sec-
tions were cut from paraffin blocks at 5 μm in thickness.
For immunohistochemical staining, the slides were
deparaffinized and then microwaved in 10 mmol/L citrate
buffer (pH 6.0) for 10minutes for antigen retrieval. After a
20minutes cool down at room temperature, the slides
were blocked using 5% goat serum and Avidin-Biotin
blocking kit (Vector Laboratories, Burlingame, CA). Next,
the slides were incubated with primary antibodies over-
night at 4 °C. The following primary antibodies were used:
anti-Ki-67 (MA5-14520, Thermo Fisher Scientific) and
anti-Brg1 (110641, Abcom). The immunoreactivity was
visualized with the Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA), using Vector NovaRED
(Vector Laboratories) as the chromogen. Slides were then
counterstained with hematoxylin solution (ThermoFisher
Scientific, Pittsburg, PA).
Protein extraction and western blot analysis
Mouse liver tissues and cells were homogenized in M-
PER Mammalian Protein Extraction Reagent (Thermo-
Fisher Scientific) containing the Halt Protease Inhibitor
Cocktail (ThermoFisher Scientific). Subsequently, protein
concentrations were determined by using the Pierce
Microplate BCA Protein Assay Kit (ThermoFisher Sci-
entific). For western blotting, proteins were boiled in Tris-
Glycine SDS Sample Buffer (Bio-Rad) for denaturation,
separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis, and transferred onto nitrocellulose
membranes (Bio-Rad). Membranes were blocked in 10%
non-fat milk in Tris-buffered saline containing 0.05%
Tween-20 for 1 hour at room temperature and then
incubated with primary antibodies at 4 °C overnight.
Afterwards, membranes were incubated with a horse-
radish peroxidase-secondary antibody (1:5000; Jackson
ImmunoResearch Laboratories Inc., West Grove, PA) at
room temperature for 1 hour. After appropriate washing,
membranes were developed with the Super Signal West
Dura Kit (ThermoFisher Scientific, Waltham, MA). The
Wang et al. Cell Death and Disease           (2020) 11:91 Page 9 of 11
Official journal of the Cell Death Differentiation Association
following antibodies were used: anti-Brg1 (110641,
Abcam), anti-c-MET (71-8000, Invitrogen), anti-total
AKT (9272, Cell Signaling Technology), anti-Phospho-
AKT (Ser473; 3787, Cell Signaling Technology), anti-
Phospho-AKT (Ser308; 13038, Cell Signaling Technology),
anti-Phospho-ERK1/2 (4370, Cell Signaling Technology),
anti-total ERK1/2 (9102, Cell Signaling Technology), anti-
GAPDH (5174, Cell Signaling Technology).
Quantitative reverse transcription real-time polymerase
chain reaction (qRT-PCR)
Total RNA was extracted from liver tissues or cells
using the Quick-RNAMiniPrep Kit (Genesee Scientific, El
Cajon, CA). cDNA was generated using the 5 × iScriptTM
RT Supermix (Bio-Rad), according to the instructions of
the manufacturer. The real-time quantitative RT-PCR
(RT-qPCR) was performed using the TaqMan Universal
PCR Master Mix (Thermo Fisher Scientific) on an ABI
Prism 7000 Sequence Detection System (Applied Biosys-
tems, Foster City, CA). Analysis of mRNA levels was
conducted with the QuantStudio Real-Time PCR software
version 1.1 (Thermo Fisher Scientific). The RT-qPCR was
conducted as follows: template denaturation at 95 °C for
10minutes, primer annealing at 95 °C for 15 s, and
extension step at 60 °C for 1 minute. Forty cycles of
amplification were used. All the primers used in the
present study are listed in Supplementary Table 7. To
determine the levels of BRG1 in our HCC collection, Gene
Expression Assays for human BRG1/SMARCA4 (ID#
Hs00231324_m1) and β-Actin (ID #4333762 T) genes
were purchased from Applied Biosystems (Foster City,
CA, USA). Quantitative values for each were calculated by
using the PE Biosystems Analysis software and expressed
as number target (NT). NT= 2−ΔCt, wherein ΔCt value of
each sample was calculated by subtracting the average Ct
value of the target gene from the average Ct value of the
β-Actin gene.
Statistical analysis
The investigators were blinded to the group allocation
during the experiment. Sample size for each experiment
was determined by power analysis (power of 0.8 with
alpha value 0.05). Animals were randomly allocated to
experimental groups and processed. No animals were
excluded from the analyses. All experiments were per-
formed at least three times. All data are presented as
means ± SD for each group. Statistical differences
between two groups were determined using the U tests
embedded in the Prism 6 software version 6.0 (Graph
Pad Software Inc., La Jolla, CA). P < 0.05 was considered
statistically significant. Our data follow a normal dis-
tribution, and the variances among the groups are
similar.
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